Search

everythinglearnresearchcommunity

for

Search:↓

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

A user is asking about increasing their dutasteride dosage from 0.5mg to up to 2.5mg and whether it improves hair loss treatment. They are seeking experiences from others who have tried higher doses.

User asks how long RU58841 bottle lasts, inquires about application, quantities, and mixing at home.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Hair loss sufferers becoming hyper aware of shedding, and the various treatments available for reducing shedding. The conversation also discussed differentiating between shedding and balding, as well as the potential side effects from using certain treatments.

Finasteride can cause side effects like erectile dysfunction and decreased libido, possibly due to increased estradiol from testosterone aromatization, especially in those with higher body fat. Side effects vary widely and may also be influenced by genetic factors or neurosteroid inhibition.

Adding exosomes to a treatment of dutasteride and minoxidil for hair loss increased hair count by 55% at 6 months and 46% at 1 year compared to the control group. The control group did not receive exosomes or PRP.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

Hair loss treatments like Dutasteride, RU58841, and Minoxidil may not work for everyone, as some individuals experience no improvement despite extensive use and research. Genetic factors can play a significant role, and standard treatments may not be effective for all.

The user has been using finasteride for over two years with mixed results and is considering starting dutasteride and oral minoxidil, though both are hard to obtain. They are also contemplating a hair transplant in the future due to diffuse thinning.

The conversation is about a person experiencing significant hair loss in the donor area after a hair transplant, with others suggesting it might be shock loss. The person is taking oral minoxidil and dutasteride to help with the issue.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

The user plans to switch to oral finasteride and oral minoxidil due to insufficient results from PRP, topical minoxidil, and mild DHT inhibitors. They seek advice on purchasing these medications from My.India, questioning its trustworthiness.

The user has been taking oral finasteride (1mg daily) and oral minoxidil (2.5mg daily) for about a year to treat hair loss and is unsure about the progress, considering switching to dutasteride and increasing the minoxidil dose. Photos were shared for comparison, and another user suggested continuing the current treatment unless the condition worsens.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

A 23-year-old male taking 0.25 mg finasteride for 40 days noticed reduced hair shedding and improved hair texture but experienced watery semen, which might be temporary. Overejaculation and finasteride can cause this, and it usually resolves, but consulting a healthcare provider is advised if it persists.

Switching brands of minoxidil and finasteride may cause changes in hair progress and increased shedding. The user noticed more shedding and thinner hair after changing brands and increasing the dosage to 5mg per day.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It also mentions ongoing human trials for hair multiplication/cloning at Yokohama National University, with skepticism about the timeline.

RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

Dutasteride users report mixed experiences, with some experiencing significant hair shedding and others seeing improvement after initial shedding. Many users switch from finasteride to dutasteride, hoping for better results, but reactions vary widely, with some facing allergies or worsening hair loss.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The conversation expresses frustration over the lack of progress in hair loss treatments, with specific mentions of Minoxidil, finasteride, and RU58841. Users discuss the slow development of new treatments and the potential of hair transplants.

A user is starting topical finasteride and minoxidil 3 times a week for hair loss and is experiencing high anxiety about the treatment's effectiveness and potential side effects. They are also taking vitamin D3 daily and are concerned about the application method and possible shedding.

The user shared their 2-year progress using finasteride and minoxidil, with significant improvement after adding dutasteride in the last year. They advise persistence with the treatment despite initial setbacks.

Microneedling depth should be customized based on hair type and scalp area, with many users finding 0.5-0.6mm effective for miniaturized hairs to avoid damage. Users report varying pain levels and results, with some preferring shorter needle lengths and others using longer ones like 1.75mm for scalp health and density improvement.

User 3 months post hair transplant, using minoxidil and dutasteride. Users discuss possible reasons for odd-looking hair strands.

The user is experiencing increased hair miniaturization despite using oral minoxidil, dutasteride, and microneedling. They are considering reintroducing finasteride and adjusting dutasteride dosage.